Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab with Chemotherapy in Untreated Adult ALL
NCT00061945Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2003
- Primary completion
- Dec 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Alemtuzumab at 6 weeks and Number of Participants Who Proceed to Course V at 8 months. Started Jun 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00061945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061945.